MENT Transdermal Gel
- User: Male
- Hormonal: Hormonal
-
Delivery type:
- Transdermal
-
Intended Duration:
- Short-Acting
- Development Stage: Phase I
- Developer(s)/researcher(s): Population Council
Details
- API: 7alpha-Methyl-19-Nortestosterone
- Target: Androgen Receptor
-
Mechanism of Action:
- Reduced Sperm Production
- Inactive Materials: Ethanol, Other Absorption Enhancers
- Regimen: 1 Application/Day
- MPT: Not Potential MPT
Product Status
Patents have been withdrawn or abandoned & no publications following 2014 Phase 1 trials
History
Early studies indicated that MENT gel suppressed steroid sex hormones over a seven-day treatment period, and that the effect was reversible when treatment ended. MENT was licensed to Schering AG, Germany as a hormone replacement therapy in 2001. After Schering's acquisition by Bayer, development was halted.